Puma Sales Slow Less Than Expected as Anta Partnership Advances
The German sportswear business is attempting to reboot its brand appeal to better compete with larger rivals Adidas and Nike.

Missteps by previous management has led the British retailer's CEO to caution that a turnaround will take up to three years.

Julian Dunkerton won a bitter battle to rejoin the board in April, prompting the resignation of all its directors.

The reshuffle comes two months after the return of Superdry founder Julian Dunkerton sparked the resignation of most of the board.

The warning comes just over a month after Julian Dunkerton returned to lead a turnaround.
ADVERTISEMENT

The return of Julian Dunkerton sparked the exit of most of its board members, including top executives.

The apparel retailer's board had opposed founder Julian Dunkerton's return, saying it would be highly disruptive and could trigger resignations.

Superdry, shares in which slumped 68 percent over the last year, has already said that it does not want founder Julian Dunkerton back, asking shareholders to vote against him
ADVERTISEMENT
The German sportswear business is attempting to reboot its brand appeal to better compete with larger rivals Adidas and Nike.
The Tata Group-owned business beat expectations, shoring up confidence in its fashion business after a period of sluggish performance.
Chasity Monroe has been appointed as the label’s chief executive as it undergoes a wider brand refresh.
The Korean firm and Medicube owner reported third quarter revenue growth of over 100 percent, mostly attributed to the expansion of its skincare range into new markets, channels and product categories.
Celebrity-makeup artist Ash K. Holm will join the “smart” mirror brand for a year-long partnership focusing on guidance and education.
Revenue growth outpaced the previous quarter in the Korean conglomerate’s domestic market, but slowed internationally.
Current president Debi Chirichella will be Hearst Magazine’s next chair.
Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge, giving the drugmaker more momentum as it expands into pills and develops even more powerful weight-loss treatments.